Patients with ER-α66-positive breast cancer generally respond favorably to endocrine therapy; however, approximately 40% of such cancers do not respond to tamoxifen therapy. A novel variant of ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

Tamoxifen (Nolvadex, Soltamox) is the most widely prescribed breast cancer therapy in the world. Some even call it the "backbone" of breast cancer treatment. Even with all that fanfare, tamoxifen ...

Tamoxifen is an oral anti-estrogen used to treat women with estrogen receptor positive breast cancer. It is taken once daily and blocks the estrogen receptor on cancer and normal cells. It ...

Background: Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and ...

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...